A Randomised Crossover Study to Assess the Usability of Two New Vision Tests in Patients With Low Vision, and Relationship of the Measures to Daily Living Tasks.
Sponsor study identifier
observational
50
1 country
1
Study Start
August 2013
Actual (reported)Primary Completion
March 2016
Actual (reported)Study Completion
March 2016
Actual (reported)Vision testing is a fundamental part of every optometry and ophthalmology assessment. Traditional vision testing charts are not able to measure vision below a certain level. Vision in this range is classified as counting fingers (CF), hand movements (HM) and light perception (LP). These measures are not very accurate or easily quantifiable. They are also poorly understood in terms of impact on quality of life. This study aims to assess new methods for measuring the vision of patients with very low vision.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2016
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 10, 2013
Actual (reported)June 12, 2013
Actual (reported)August 2013
Actual (reported)March 2016
Actual (reported)March 2016
Actual (reported)Comparison of VA measured with FrACT and BRVT vision tests
Single visit
Relationship between VA and ability to carry out daily living tasks.
Single time point
Undergo testing with BRVT first, FrACT second.
Undergo testing with FrACT first, BRVT second.
Patients with low vision attending outpatient clinics in Oxford Eye Hospital.
Oxford University Hospitals NHS Trust
Oxford, Oxfordshire, OX3 9DU, United Kingdom
Jolly JK, Gray JM, Salvetti AP, Han RC, MacLaren RE. A Randomized Crossover Study to Assess the Usability of Two New Vision Tests in Patients with Low Vision. Optom Vis Sci. 2019 Jun;96(6):443-452. doi: 10.1097/OPX.0000000000001380.
Robert E MacLaren, DPhil
University of Oxford
50 participants (actual enrollment reported by the registry).
First Submitted
June 10, 2013
First Posted
June 12, 2013
Study Start
August 2013
Actual (reported)VITAL - Individualising Therapy for Neovascular AMD With Aflibercept
Contact the study team to confirm eligibility.
Primary Completion
March 2016
Actual (reported)Study Completion
March 2016
Actual (reported)Last Updated
June 13, 2019
Record last verified: 2018-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: